Market Overview:
The global Interleukin 17A market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of chronic diseases, increasing R&D investments for novel therapies, and growing demand for Interleukin 17A drugs. The global Interleukin 17A market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into ABY-035, CNTO-6785, DLX-2882 and others. On the basis of application, the market is segmented into chronic pain reliefs treatments; liver cancer treatments; kidney cancer treatments; psoriasis treatment and other applications. The North America region dominates this market followed by Europe due to high prevalence rate of chronic diseases in these regions.
Product Definition:
Interleukin 17A is a cytokine that is produced by T cells and mast cells. It is important in the immune response against infection and in the development of autoimmune diseases.
ABY-035:
ABY-035 is a small molecule that acts as an inhibitor of nuclear factor ?-B signaling pathway. This molecule has shown to have potent anti-inflammatory activity in in vitro and in vivo models. It also shows promising safety and efficacy profile for treating atopic dermatitis, psoriasis, septic shock, and endotoxin shock.
CNTO-6785:
CNTO-6785 is a human monoclonal antibody that binds to the Interleukin 17A (IL-17A) receptor. CNTO-6785 was developed by Cell Signaling Technology as an allogeneic therapeutic protein for the treatment of patients with B cell acute lymphoblastic leukemia and relapsed or refractory large B cell lymphoma, who are resistant to chemotherapy and radiation therapy.
Application Insights:
The chronic pain segment dominated the global market in terms of revenue in 2017. Interleukin 17 is a popular choice among patients suffering from chronic pain due to its ability to reduce inflammation and hypersensitivity response. It reduces nociceptive input by modulating inflammatory mediators such as prostaglandins, leukotrienes, cytokines and neuropeptides at the spinal cord level. This factor is responsible for increased use of interleukin 17 products for treatment of chronic pain disorders across the globe.
However, liver cancer held the highest share among applications in 2017 owing to high incidence rates coupled with rising demand for innovative drugs developed specifically for treating liver cancer.
Regional Analysis:
North America accounted for the largest share of global revenue in 2017. The region is expected to maintain its dominance during the forecast period on account of rising product demand and presence of key players in this region. In addition, increasing government funding for cancer research coupled with favorable regulations aimed at promoting novel drugs is also anticipated to drive market growth over the forecast period.
Asia Pacific is estimated to be fastest-growing regional market from 2018 to 2030 owing to high prevalence of chronic diseases such as cancer and autoimmune disorders that are driving demand for interleukin 17A products used for diagnosis and treatment purposes. In addition, growing awareness about advanced therapies among patients will fuel industry growth over the next eight years (from 2018 to 2030). Moreover, rapidly developing healthcare infrastructure coupled with increasing disposable income levels in emerging economies such as China & India will further boost industry expansion over the coming years (2018 -2030).
Growth Factors:
- Increasing incidence of autoimmune diseases: The increasing incidence of autoimmune diseases is one of the key growth drivers for the Interleukin 17A market. Autoimmune diseases are caused due to the abnormal functioning of the immune system, which leads to inflammation and damage to tissues and organs. The global prevalence of autoimmune diseases is estimated to be around 235 million, and it is expected to increase further in the coming years. This will create a high demand for Interleukin 17A drugs, thereby driving the growth of this market.
- Rising awareness about autoimmune diseases: There is a growing awareness among people about autoimmune diseases and their symptoms. This has led to an increase in the number of people who are seeking treatment for these conditions. This will create a high demand for Interleukin 17A drugs in the coming years, thereby propellingthe growthof thismarket segment .
Scope Of The Report
Report Attributes
Report Details
Report Title
Interleukin 17A Market Research Report
By Type
ABY-035, CNTO-6785, DLX-2882, Others
By Application
Chronic Pain, Liver Cancer, Kidney Cancer, Others
By Companies
AbbVie Inc, Abeome Corporation, Affibody AB, Cell Medica Limited, Eli Lilly and Company, Johnson & Johnson, Merck KGaA, Novartis AG, Orega Biotech SAS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
198
Number of Tables & Figures
139
Customization Available
Yes, the report can be customized as per your need.
Global Interleukin 17A Market Report Segments:
The global Interleukin 17A market is segmented on the basis of:
Types
ABY-035, CNTO-6785, DLX-2882, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Pain, Liver Cancer, Kidney Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc
- Abeome Corporation
- Affibody AB
- Cell Medica Limited
- Eli Lilly and Company
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Orega Biotech SAS
Highlights of The Interleukin 17A Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ABY-035
- CNTO-6785
- DLX-2882
- Others
- By Application:
- Chronic Pain
- Liver Cancer
- Kidney Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Interleukin 17A Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Interleukin 17A is a type of cytokine that helps the body fight infection.
Some of the major players in the interleukin 17a market are AbbVie Inc, Abeome Corporation, Affibody AB, Cell Medica Limited, Eli Lilly and Company, Johnson & Johnson, Merck KGaA, Novartis AG, Orega Biotech SAS.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Interleukin 17A Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Interleukin 17A Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Interleukin 17A Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Interleukin 17A Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Interleukin 17A Market Size & Forecast, 2020-2028
4.5.1 Interleukin 17A Market Size and Y-o-Y Growth
4.5.2 Interleukin 17A Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ABY-035
5.2.2 CNTO-6785
5.2.3 DLX-2882
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Chronic Pain
6.2.2 Liver Cancer
6.2.3 Kidney Cancer
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Interleukin 17A Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Interleukin 17A Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ABY-035
9.6.2 CNTO-6785
9.6.3 DLX-2882
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Chronic Pain
9.10.2 Liver Cancer
9.10.3 Kidney Cancer
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ABY-035
10.6.2 CNTO-6785
10.6.3 DLX-2882
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Chronic Pain
10.10.2 Liver Cancer
10.10.3 Kidney Cancer
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ABY-035
11.6.2 CNTO-6785
11.6.3 DLX-2882
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Chronic Pain
11.10.2 Liver Cancer
11.10.3 Kidney Cancer
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ABY-035
12.6.2 CNTO-6785
12.6.3 DLX-2882
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Chronic Pain
12.10.2 Liver Cancer
12.10.3 Kidney Cancer
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ABY-035
13.6.2 CNTO-6785
13.6.3 DLX-2882
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Chronic Pain
13.10.2 Liver Cancer
13.10.3 Kidney Cancer
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Interleukin 17A Market: Competitive Dashboard
14.2 Global Interleukin 17A Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie Inc
14.3.2 Abeome Corporation
14.3.3 Affibody AB
14.3.4 Cell Medica Limited
14.3.5 Eli Lilly and Company
14.3.6 Johnson & Johnson
14.3.7 Merck KGaA
14.3.8 Novartis AG
14.3.9 Orega Biotech SAS
